Granules India Limited

Granules India Limited

Granules India Limited has informed the Exchange about the resignation of a Director/KMP/SMP.

Granules India Limited

Granules India Limited has informed the Exchange about the change in management, with Mr. Sanjay Kumar, Chief Strategy Officer, transferring to a wholly-owned subsidiary, Ascelis Peptides Private Limited, as its CEO, effective August 13, 2026.

Granules India Limited

Granules India Limited has held its 35th Annual General Meeting (AGM) on August 06, 2026, where the company's financial statements for FY 2025-26 were adopted, a final dividend of Rs. 1.75 paise per equity share was declared, and Ms. Priyanka Chigurupati was re-appointed as an Executive Director.

Granules India Limited

Granules India Limited has announced its Q1 FY27 financial results, with revenue growing 22% to INR1,477 crores, gross margin at 65.6%, EBITDA growing 37% to INR339 crores, and profit after tax growing 60% to INR180 crores. The company has also highlighted its return on capital, which has improved to 18%, and its net debt to EBITDA ratio is now 0.07x, making it debt-free for all practical purposes.

Granules India Limited

Granules India Limited has informed the Exchange about the link of recording for the Analysts/Institutional Investor Meet/Con. Call Updates. The recording is available on the company's website.

Granules India Limited

Granules India Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026 regarding the utilization of proceeds from its preferential issue of equity shares completed in February 2026. The report, issued by India Ratings & Research, confirms no deviation from the stated objects of the issue, based on management undertakings and a statutory auditor certificate. The filing is made pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. No adverse findings were noted, and the report is being submitted to NSE and BSE for record.

Granules India Limited

Granules India Limited notified the National Stock Exchange that it will share a presentation related to an analysts/institutional investor meet or conference call. The announcement does not disclose any specific financial results, strategic initiatives, or other material information. It is a routine procedural update regarding investor communication.

Granules India Limited

Granules India Limited announced its unaudited financial results for Q1 FY27, reporting revenue from operations of INR 14,768 million, a 22% year‑on‑year increase. EBITDA rose to INR 3,389 million (+37% YoY) and profit after tax reached INR 1,800 million (+60% YoY). Net debt declined sharply to INR 1,012 million, reducing the net debt‑to‑EBITDA ratio to 0.07x, while ROCE improved to 18.0%. The company highlighted strong performance across its API, finished dosage, PFI and peptides CDMO segments and reiterated focus on regulatory excellence and portfolio transformation.

Granules India Limited

Granules India Limited

Granules India Limited has published a copy of a newspaper advertisement regarding the notice of its 35th Annual General Meeting and e-voting information in Business Standard and Nava Telangana on July 16, 2026.

Granules India Limited

Granules India Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 06, 2026. The company has submitted its Integrated Annual Report for the FY 2025-26 along with the Notice of the 35th Annual General Meeting.

Granules India Limited

Granules India Limited has announced the schedule of its Q1 FY27 earnings conference call, to be held on July 21st, 2026, at 5:00 PM IST.

Granules India Limited

Granules India Limited has secured Sole First-to-File ANDA status for Sodium Oxybate Extended-Release for Oral Suspension, a generic equivalent of LUMRYZ, marking its second such achievement in the complex generics segment.

Granules India Limited

Granules India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in the securities of the Company shall remain closed for all Insiders including the Designated Persons and their immediate relatives from July 01, 2026 till 48 hours after the declaration of the un-audited financial results for the first quarter of FY 27 ending on June 30, 2026.